Company Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial.
It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Alexander Sapir |
Contact Details
Address: 26 Landsdowne Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 651 8851 |
| Website | fulcrumtx.com |
Stock Details
| Ticker Symbol | FULC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001680581 |
| CUSIP Number | 359616109 |
| ISIN Number | US3596161097 |
| Employer ID | 47-4839948 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander C. Sapir | Chief Executive Officer, President and Director |
| Alan A. Musso C.M.A., CPA | Chief Financial Officer |
| Curtis G. Oltmans J.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder |
| Dr. Michael R. Green | Founder |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder |
| Dr. Tsun-Huei Lee M.D., Ph.D. | Founder |
| Dr. Danny Reinberg | Founder |
| Gregory Tourangeau | Controller and Principal Accounting Officer |
| Dr. Jeffrey W. Jacobs Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | DEFR14A | Filing |
| May 2, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |